Five-year outcomes with PCI guided by fractional flow reserve
Five-year outcomes with PCI guided by fractional flow reserve
Background: we hypothesized that fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) would be superior to medical therapy as initial treatment in patients with stable coronary artery disease.
Methods: among 1220 patients with angiographically significant stenoses, those in whom at least one stenosis was hemodynamically significant (FFR, ≤0.80) were randomly assigned to FFR-guided PCI plus medical therapy or to medical therapy alone. Patients in whom all stenoses had an FFR of more than 0.80 received medical therapy and were entered into a registry. The primary end point was a composite of death, myocardial infarction, or urgent revascularization.
Results: a total of 888 patients underwent randomization (447 patients in the PCI group and 441 in the medical-therapy group). At 5 years, the rate of the primary end point was lower in the PCI group than in the medical-therapy group (13.9% vs. 27.0%; hazard ratio, 0.46; 95% confidence interval [CI], 0.34 to 0.63; P<0.001). The difference was driven by urgent revascularizations, which occurred in 6.3% of the patients in the PCI group as compared with 21.1% of those in the medical-therapy group (hazard ratio, 0.27; 95% CI, 0.18 to 0.41). There were no significant differences between the PCI group and the medical-therapy group in the rates of death (5.1% and 5.2%, respectively; hazard ratio, 0.98; 95% CI, 0.55 to 1.75) or myocardial infarction (8.1% and 12.0%; hazard ratio, 0.66; 95% CI, 0.43 to 1.00). There was no significant difference in the rate of the primary end point between the PCI group and the registry cohort (13.9% and 15.7%, respectively; hazard ratio, 0.88; 95% CI, 0.55 to 1.39). Relief from angina was more pronounced after PCI than after medical therapy.
Conclusions: in patients with stable coronary artery disease, an initial FFR-guided PCI strategy was associated with a significantly lower rate of the primary composite end point of death, myocardial infarction, or urgent revascularization at 5 years than medical therapy alone. Patients without hemodynamically significant stenoses had a favorable long-term outcome with medical therapy alone. (Funded by St. Jude Medical and others; FAME 2 ClinicalTrials.gov number, NCT01132495 .).
Aged, Angina Pectoris/therapy, Antihypertensive Agents/therapeutic use, Coronary Disease/drug therapy, Coronary Stenosis/drug therapy, Drug-Eluting Stents, Female, Follow-Up Studies, Fractional Flow Reserve, Myocardial, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Infarction/epidemiology, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors/therapeutic use, Retreatment/statistics & numerical data
250-259
Xaplanteris, Panagiotis
6901700d-6ac8-41b6-8e63-2768d38789b1
Fournier, Stephane
b92de86c-fd9d-48df-a9a1-249d34bdd6ac
Pijls, Nico H J
90717d6e-0756-4d55-ba7f-d4f7377ea048
Fearon, William F
0cd8b847-758f-4501-bd76-543e630f3179
Barbato, Emanuele
50106486-a9cd-4c08-9ee7-74d049a9356d
Tonino, Pim A L
f22d79b3-5ee7-4780-b25c-df728ce09a3b
Engstrøm, Thomas
ac797dfe-9ad1-4aca-a7d5-53b13b4422de
Kääb, Stefan
03ae2a2c-1e5f-4de8-b9e7-95bd559fc07a
Dambrink, Jan-Henk
2c962bf2-b825-4891-a3b6-b84fa6aa8ab1
Rioufol, Gilles
87163c97-9ed4-477a-9692-6ac8506fcd9f
Toth, Gabor G
af8702a6-1b7d-4eea-92d0-39e3c3dce06a
Piroth, Zsolt
987ac008-d51d-4a12-a67c-499766e2fba5
Witt, Nils
36920472-6c35-4858-916e-040dbc5e29ce
Fröbert, Ole
6ed61821-ddc6-4acc-ba71-888007209070
Kala, Petr
7f4cfffe-5789-46ab-8a22-eb77a078f3f2
Linke, Axel
f5304b6d-2bb4-4a87-88aa-ff1d1e71d529
Jagic, Nicola
0669a4c7-22be-40d1-aacd-1822a34ea175
Mates, Martin
f784eee6-230f-480c-80f6-f1275c0e454a
Mavromatis, Kreton
f5504621-1e1a-425f-a3ce-4e68d697dffb
Samady, Habib
3de77cd5-a7ae-4456-8306-6ab968976e84
Irimpen, Anand
1423e29e-5bc8-44f0-acfc-41320527c14c
Oldroyd, Keith
c14c5917-9f7f-46b6-852b-9163add073f7
Campo, Gianluca
56959271-26a6-44d1-9aed-feedaf093b96
Rothenbühler, Martina
be1f8700-d113-465b-bfbc-b2a5d919157d
Jüni, Peter
1448ad34-a0d4-4faa-962b-abf202246167
De Bruyne, Bernard
6c86ad29-d853-4e59-9633-f536a17efd4e
Curzen, Nicholas
70f3ea49-51b1-418f-8e56-8210aef1abf4
19 July 2018
Xaplanteris, Panagiotis
6901700d-6ac8-41b6-8e63-2768d38789b1
Fournier, Stephane
b92de86c-fd9d-48df-a9a1-249d34bdd6ac
Pijls, Nico H J
90717d6e-0756-4d55-ba7f-d4f7377ea048
Fearon, William F
0cd8b847-758f-4501-bd76-543e630f3179
Barbato, Emanuele
50106486-a9cd-4c08-9ee7-74d049a9356d
Tonino, Pim A L
f22d79b3-5ee7-4780-b25c-df728ce09a3b
Engstrøm, Thomas
ac797dfe-9ad1-4aca-a7d5-53b13b4422de
Kääb, Stefan
03ae2a2c-1e5f-4de8-b9e7-95bd559fc07a
Dambrink, Jan-Henk
2c962bf2-b825-4891-a3b6-b84fa6aa8ab1
Rioufol, Gilles
87163c97-9ed4-477a-9692-6ac8506fcd9f
Toth, Gabor G
af8702a6-1b7d-4eea-92d0-39e3c3dce06a
Piroth, Zsolt
987ac008-d51d-4a12-a67c-499766e2fba5
Witt, Nils
36920472-6c35-4858-916e-040dbc5e29ce
Fröbert, Ole
6ed61821-ddc6-4acc-ba71-888007209070
Kala, Petr
7f4cfffe-5789-46ab-8a22-eb77a078f3f2
Linke, Axel
f5304b6d-2bb4-4a87-88aa-ff1d1e71d529
Jagic, Nicola
0669a4c7-22be-40d1-aacd-1822a34ea175
Mates, Martin
f784eee6-230f-480c-80f6-f1275c0e454a
Mavromatis, Kreton
f5504621-1e1a-425f-a3ce-4e68d697dffb
Samady, Habib
3de77cd5-a7ae-4456-8306-6ab968976e84
Irimpen, Anand
1423e29e-5bc8-44f0-acfc-41320527c14c
Oldroyd, Keith
c14c5917-9f7f-46b6-852b-9163add073f7
Campo, Gianluca
56959271-26a6-44d1-9aed-feedaf093b96
Rothenbühler, Martina
be1f8700-d113-465b-bfbc-b2a5d919157d
Jüni, Peter
1448ad34-a0d4-4faa-962b-abf202246167
De Bruyne, Bernard
6c86ad29-d853-4e59-9633-f536a17efd4e
Curzen, Nicholas
70f3ea49-51b1-418f-8e56-8210aef1abf4